What are Halozyme Therapeutics's total assets?

Halozyme Therapeutics (HALO) holds $2.7B in total assets, up 21.7% year over year.

How much debt does Halozyme Therapeutics have?

Halozyme Therapeutics carries $2.2B in total debt against $219.6M of shareholders' equity, a debt-to-equity ratio of 9.91.

How much cash does Halozyme Therapeutics have?

Halozyme Therapeutics holds $312.0M in cash and equivalents.

Can Halozyme Therapeutics cover its short-term obligations?

Its current ratio is 2.76 — current assets exceed current liabilities.

Where does Halozyme Therapeutics's balance sheet data come from?

Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Halozyme Therapeutics HALO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$312.01M+129%	$136.42M-67.5%	$419.67M+578%	$61.86M-64.9%	$176.33M+52.2%
Restricted cash	——	——	——	——	——
Accounts receivable, net	$457.99M+7.4%	$426.27M+24.1%	$343.54M+9.0%	$315.07M+3.6%	$304.03M+5.5%
Inventories	$14.84M-28.5%	$20.77M-29.8%	$29.6M-7.8%	$32.08M-4.1%	$33.44M-39.5%
Raw materials	$21.9M+0.2%	$21.87M+15.3%	$18.96M+6.6%	$17.79M-3.4%	$18.42M-23.3%
Work in process	$35.04M+13.3%	$30.92M-11.3%	$34.84M+12.6%	$30.93M-15.6%	$36.65M+21.5%
Finished goods	$113.37M-21.5%	$144.45M-10.6%	$161.59M-2.0%	$164.87M+15.1%	$143.24M+0.2%
Prepaid expenses and other current assets	$70.96M+9.8%	$64.64M-31.9%	$94.96M+23.9%	$76.65M+71.8%	$44.62M+14.5%
Trading assets	$8.87M-1.4%	$9M-96.4%	$251.44M-32.6%	$373.25M-15.3%	$440.89M+40.0%
Derivative assets	——	——	——	——	——
Total current assets	$1B+21.5%	$825.21M-37.9%	$1.33B+18.4%	$1.12B-11.0%	$1.26B+16.3%
Property and equipment, net	$46.93M+5.6%	$44.44M+9.5%	$40.58M+2.5%	$39.6M-1.5%	$40.22M-1.6%
Accumulated depreciation	$35.22M+6.2%	$33.16M+6.8%	$31.06M+6.3%	$29.21M+7.3%	$27.23M+7.1%
Operating lease right-of-use assets	——	——	$30.85M-3.4%	$31.92M-2.1%	$32.59M-4.6%
Goodwill	$582.32M+0.3%	$580.36M+39.2%	$416.82M0.0%	$416.82M0.0%	$416.82M0.0%
Intangible assets, net	$951.96M-3.0%	$981.47M+227%	$299.84M-5.6%	$317.61M-5.3%	$335.37M-16.5%
Deferred tax assets	$47.53M+10.7%	$42.92M+422%	$8.22M-59.3%	$20.21M+289%	$5.19M—
Other non-current assets	$15.29M+39.8%	$10.93M-39.1%	$17.95M-16.1%	$21.38M+45.2%	$14.73M-15.4%
Available-for-sale securities	$0—	$0-100%	$30.85M-72.7%	$113.07M-13.5%	$130.71M-20.9%
Total assets	$2.67B+5.8%	$2.53B+13.7%	$2.22B+8.1%	$2.05B-6.5%	$2.2B+6.4%
Accounts payable	$14.1M-32.5%	$20.9M+36.1%	$15.36M-17.8%	$18.69M-6.9%	$20.07M+95.9%
Accrued expenses	$94.6M-9.3%	$104.35M+85.8%	$56.16M-9.5%	$62.04M+117%	$28.64M+9.1%
Accrued compensation	$18.14M-36.6%	$28.62M+80.8%	$15.83M+28.0%	$12.37M+19.6%	$10.34M-57.6%
Deferred revenue	——	——	——	——	——
Current portion of long-term debt	——	——	——	——	——
Operating lease liabilities, current	$32.42M-6.2%	$34.57M+23.0%	$28.1M-3.0%	$28.97M-1.4%	$29.39M-4.3%
Contract liabilities	$32.95M-7.2%	$35.48M+324%	$8.37M0.0%	$8.37M-9.1%	$9.21M-10.9%
Income taxes payable	$48.01M+8.8%	$44.15M+69.7%	$26.02M+4.3%	$24.96M-56.9%	$57.96M+87.0%
Total current liabilities	$363.21M+105%	$177.09M-78.8%	$837.23M+523%	$134.28M-10.7%	$150.38M+8.1%
Long-term debt	$1.94B-9.6%	$2.14B+168%	$800.07M-47.0%	$1.51B+0.1%	$1.51B+0.1%
Operating Lease Liabilities (Total)	$32.42M-6.2%	$34.57M+23.0%	$28.1M-3.0%	$28.97M-1.4%	$29.39M-4.3%
Other non-current liabilities	$106.45M-6.5%	$113.86M+58.6%	$71.8M-7.7%	$77.77M+37.8%	$56.44M+3.1%
Total liabilities	$2.45B-0.9%	$2.48B+44.2%	$1.72B-0.2%	$1.72B+0.4%	$1.71B+0.9%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	300M0.0%	300M0.0%	300M0.0%	300M0.0%	300M+243,802%
Additional paid-in capital	$27.39M+128%	$12M-49.8%	$23.91M—	$0-100%	$7.6M—
Retained earnings	$204.84M+274%	$54.79M-89.1%	$502.15M+39.1%	$361.03M-24.5%	$477.96M+32.8%
Accumulated other comprehensive income (loss)	-$12.7M+29.8%	-$18.09M+18.7%	-$22.26M+21.6%	-$28.4M-732%	-$3.41M-189%
Total stockholders' equity	$219.64M+350%	$48.81M-90.3%	$503.92M+51.4%	$332.75M-31.0%	$482.27M+32.6%
Total liabilities and stockholders' equity	$2.67B+5.8%	$2.53B+13.7%	$2.22B+8.1%	$2.05B-6.5%	$2.2B+6.4%
Available-for-Sale Debt Securities	$8.87M-1.4%	$9M-96.8%	$282.3M-42.0%	$486.32M-14.9%	$571.59M+19.0%
Available-for-Sale Debt Securities - Amortized Cost	$8.88M-1.4%	$9M-96.8%	$282.04M-42.0%	$486.37M-14.9%	$571.61M+19.0%
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	——	——	——
Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current	$457.99M+3.8%	$441.27M+27.5%	$346.04M+9.4%	$316.34M+3.8%	$304.62M-1.2%
Debt securities - current	$8.87M-1.4%	$9M-96.8%	$282.3M-42.0%	$486.32M-14.9%	$571.59M+19.0%
Derivatives	——	——	——	——	——
Finished goods	$113.37M-21.5%	$144.45M-10.6%	$161.59M-2.0%	$164.87M+15.1%	$143.24M+0.2%
Prepaid expenses and other	$121.87M+3.1%	$118.19M-21.5%	$150.65M+13.3%	$133.02M+32.7%	$100.23M-16.2%
Derivative Assets, Current	——	——	——	——	——
Derivative Assets - Fair Value	——	——	——	——	——
Unbilled Revenue	$0-100%	$15M+500%	$2.5M+97.5%	$1.27M+112%	$596K-97.1%
Derivative Assets, Non-Current	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Finite Lived Intangible Assets - Gross	$1.24B0.0%	$1.24B—	——	——	——
Net Investment in Lease	$35.3M-6.4%	$37.7M+22.2%	$30.85M-3.4%	$31.92M-2.1%	$32.59M-4.6%
Intangible assets — net	$951.96M-3.0%	$981.47M—	——	——	——
Other intangible assets—net	$951.96M-3.0%	$981.47M+182%	$348.54M-4.8%	$366.31M-4.6%	$384.07M-4.4%
Operating lease right-of-use assets	$35.3M-6.4%	$37.7M+22.2%	$30.85M-3.4%	$31.92M-2.1%	$32.59M-4.6%
Other Assets	$15.29M+39.8%	$10.93M-39.1%	$17.95M-16.1%	$21.38M+45.2%	$14.73M-15.4%
Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	$82.23M+0.1%	$82.14M+15.0%	$71.42M-0.1%	$71.52M-1.8%	$72.82M-3.0%
Property, plant and equipment at cost	$82.15M+5.9%	$77.6M+8.3%	$71.63M+4.1%	$68.81M+2.0%	$67.45M+1.7%
Operating Lease Right-of-Use Assets in Other Assets	$35.3M-6.4%	$37.7M+22.2%	$30.85M-3.4%	$31.92M-2.1%	$32.59M-4.6%
Prepaid Expenses, Non-Current	$50.92M-4.9%	$53.55M-3.9%	$55.7M-1.2%	$56.37M+1.4%	$55.61M-31.0%
Other Commercial Liabilities	$140.37M-10.1%	$156.19M+40.5%	$111.18M-3.8%	$115.59M-11.3%	$130.31M+1.1%
Contract Liabilities and Refund Liability	$44.55M-4.4%	$46.59M-3.8%	$48.44M-12.0%	$55.06M+4.0%	$52.94M-3.0%
Accrued Liabilities, Current	$140.37M-10.1%	$156.19M+40.5%	$111.18M-3.8%	$115.59M-11.3%	$130.31M+1.1%
Derivative Liability, Current	$6.6M-14.3%	$7.7M—	——	——	——
Derivative Liabilities - Fair Value	$6.6M-14.3%	$7.7M-9.4%	$8.5M-14.1%	$9.9M+1,000%	$900K—
Accrued expenses and other liabilities	$246.82M-8.6%	$270.06M+47.6%	$182.98M-5.4%	$193.36M+3.5%	$186.74M+1.7%
Total debt	$2.18B0.0%	$2.18B+41.5%	$1.54B+0.1%	$1.54B+0.1%	$1.54B0.0%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	118.5M+0.6%	117.8M+0.2%	117.5M-0.1%	117.6M-4.5%	123.2M0.0%
Convertible Preferred Stock Authorized Shares	20M0.0%	20M0.0%	20M0.0%	20M0.0%	20M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$27.39M+128%	$12M-49.8%	$23.91M—	$0-100%	$7.6M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$118K0.0%	$118K0.0%	$118K0.0%	$118K-4.1%	$123K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Unrealized Gains on Investments	$0—	$0-100%	$277K-3.5%	$287K-35.9%	$448K-24.3%
Unrealized Losses on Investments (Before Tax)	$5K+150%	$2K-86.7%	$15K-95.5%	$337K-27.1%	$462K-41.9%
AOCI - Cash Flow Hedge Reclassification (Next 12 Months)	——	——	——	——	——
Cumulative Cost Basis	$82.15M+5.9%	$77.6M+8.3%	$71.63M+4.1%	$68.81M+2.0%	$67.45M+1.7%
Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current	$468.25M+3.9%	$450.88M+27.4%	$353.84M+9.3%	$323.7M+3.9%	$311.6M-1.8%
Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current	$10.26M+6.8%	$9.61M+23.1%	$7.8M+6.0%	$7.36M+5.5%	$6.98M-20.1%
Accrued Liabilities, Noncurrent	$106.45M-6.5%	$113.86M+58.6%	$71.8M-7.7%	$77.77M+37.8%	$56.44M+3.1%
Accrued outsourced manufacturing expenses	$9.11M-22.7%	$11.78M+39.7%	$8.43M-15.4%	$9.96M+33.4%	$7.47M-55.3%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$5K+150%	$2K-86.7%	$15K-95.5%	$337K-27.1%	$462K-41.9%
Gross Unrealized Gains	$0—	$0-100%	$277K-3.5%	$287K-35.9%	$448K-24.3%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$0—	$0-100%	$30.85M-72.7%	$113.07M-13.5%	$130.71M-20.9%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$8.87M-1.4%	$9M-96.4%	$251.44M-32.6%	$373.25M-15.3%	$440.89M+40.0%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%
Common stock, shares issued (in shares)	$118.52M+0.6%	$117.78M+0.2%	$117.52M-0.1%	$117.62M-4.5%	$123.17M0.0%
Common Stock, Shares, Outstanding	$118.52M+0.6%	$117.78M+0.2%	$117.52M-0.1%	$117.62M-4.5%	$123.17M0.0%
Contract assets	$0-100%	$15M+500%	$2.5M+97.5%	$1.27M+112%	$596K-97.1%
Contract with Customer, Liability	$32.95M-7.2%	$35.48M+324%	$8.37M0.0%	$8.37M-9.1%	$9.21M-10.9%
Accrued sales returns	$44.55M-4.4%	$46.59M-3.8%	$48.44M-12.0%	$55.06M+4.0%	$52.94M-3.0%
Available-for-sale securities, allowance for credit loss	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$8.88M-1.4%	$9M-96.8%	$282.04M-42.0%	$486.37M-14.9%	$571.61M+19.0%
Estimated Fair Value	$8.87M-1.4%	$9M-96.8%	$282.3M-42.0%	$486.32M-14.9%	$571.59M+19.0%
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——	——
Deferred income taxes	——	——	——	——	——
Derivatives	——	——	——	——	——
Derivative Liability, Noncurrent	$10.5M-30.5%	$15.1M-22.2%	$19.4M-22.1%	$24.9M+822%	$2.7M—
Thereafter	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$291.25M+11.3%	$261.73M—	——	——	——
2028	——	——	——	——	——
2030	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
Gross Carrying Amount	$1.24B0.0%	$1.24B—	——	——	——
Inventory, Net Including Long-term Portion	$170.31M-13.7%	$197.24M-8.4%	$215.39M+0.8%	$213.59M+7.7%	$198.31M—
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$20M0.0%	$20M0.0%	$20M0.0%	$20M0.0%	$20M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	$75.29M+4.7%	$71.93M+28.4%	$56.03M+11.8%	$50.13M+19.4%	$41.99M+15.6%
Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Halozyme Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Halozyme Therapeutics's total assets?: Halozyme Therapeutics (HALO) holds $2.7B in total assets, up 21.7% year over year.
How much debt does Halozyme Therapeutics have?: Halozyme Therapeutics carries $2.2B in total debt against $219.6M of shareholders' equity, a debt-to-equity ratio of 9.91.
How much cash does Halozyme Therapeutics have?: Halozyme Therapeutics holds $312.0M in cash and equivalents.
Can Halozyme Therapeutics cover its short-term obligations?: Its current ratio is 2.76 — current assets exceed current liabilities.
Where does Halozyme Therapeutics's balance sheet data come from?: Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.